Crossmark

Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies

Published Online: 2022-10-24

Published Print: 2022-12

Authors

Atluri, Himachandana

Gerstein, Yoheved S.

DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
License Information

Text and Data Mining valid from 2022-10-24

Version of Record valid from 2022-10-24
More Information

Article History

Accepted: 24 September 2022

First Online: 24 October 2022

Declarations

:

: The authors declare the following potential conflicts of interest for the research, authorship, and/or publication of this article. Himachandana Atluri and Yoheved S. Gerstein have no relevant financial or non-financial interests to disclose. Courtney D. DiNardo has received research funding from Abbvie, Agios/Servier, Astex, Calithera, Celgene/BMS, Cleave, Foghorn, ImmuneOnc, and Loxo. She has also received honoraria/consulting fees from Abbvie, Agios/Servier, Astellas, Celgene/BMS, Cleave, Foghorn, Genentech, GenMab, GSK, Novartis, Notable Labs, and Takeda.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current